Andere talen SAB Biotherapeutics, Inc.

Aandelen

SABS

US78397T2024

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,02 ^USD	-1,95%		+0,25%	-41,53%

16/04	SAB Biotherapeutics, Inc. Geeft SAB-142 Proefupdate	CI
02/04	SAB BIOTHERAPEUTICS, INC. : HC Wainwright nog altijd een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

SAB Biotherapeutics Provides SAB-142 Trial Update	16/04
SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	16/04
SAB Biotherapeutics : Regulation FD Disclosure - Form 8-K	15/04
SAB Biotherapeutics to Present at INNODIA Annual Meeting	08/04
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference	04/04
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	01/04
SAB Biotherapeutics : Reports Full Year 2023 Operating and Financial Results March 29, 2024 - Form 8-K	29/03
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	29/03
SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline	25/03
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	25/03
Sab Biotherapeutics, Inc. Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	25/03
SAB Biotherapeutics to Present at the BIO CEO and Investor Conference	26/02
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference	23/02
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	09/02
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	08/02
SAB Biotherapeutics Executive Chairman Samuel Reich Adds CEO Role	02/02
SAB Biotherapeutics Announces Executive Leadership Change	02/02
SAB Biotherapeutics, Inc. Announces CEO Changes	02/02
SAB Biotherapeutics Regains Nasdaq Compliance	24/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SAB Biotherapeutics, Inc.

Aandelen

SABS

US78397T2024

Andere talen

Filters